Tags

Type your tag names separated by a space and hit enter

[Limits of conventional oral and transdermal medication in Parkinson's disease].
Rev Neurol. 2012; 55 Suppl 1:S3-6.RN

Abstract

At the present time, we have effective and potent antiparkinsonian drugs available which allow patients to have an acceptable functional capacity during the early years of Parkinson's disease. Yet, as time goes by, motor and functional deterioration develop, partly due to the presence of motor and non-motor complications. The conventional medication is unable to provide an adequate response if the motor fluctuations are beyond 3-4 hours of duration. At this point, it is reasonable to consider other therapies; among them subcutaneous apomorphine injection must be taken into account due to its simplicity and efficacy and later on, subcutaneous apomorphine infusion. Apomorphine is a very effective and clearly underused drug in the treatment of advanced Parkinson's disease.

Authors+Show Affiliations

Fundacion Jimenez Diaz, 28040 Madrid, Espana.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

spa

PubMed ID

23169231

Citation

García-Ruiz, Pedro J., and M Rosario Luquin. "[Limits of Conventional Oral and Transdermal Medication in Parkinson's Disease]." Revista De Neurologia, vol. 55 Suppl 1, 2012, pp. S3-6.
García-Ruiz PJ, Luquin MR. [Limits of conventional oral and transdermal medication in Parkinson's disease]. Rev Neurol. 2012;55 Suppl 1:S3-6.
García-Ruiz, P. J., & Luquin, M. R. (2012). [Limits of conventional oral and transdermal medication in Parkinson's disease]. Revista De Neurologia, 55 Suppl 1, S3-6.
García-Ruiz PJ, Luquin MR. [Limits of Conventional Oral and Transdermal Medication in Parkinson's Disease]. Rev Neurol. 2012;55 Suppl 1:S3-6. PubMed PMID: 23169231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Limits of conventional oral and transdermal medication in Parkinson's disease]. AU - García-Ruiz,Pedro J, AU - Luquin,M Rosario, PY - 2012/11/22/entrez PY - 2012/10/20/pubmed PY - 2014/8/19/medline SP - S3 EP - 6 JF - Revista de neurologia JO - Rev Neurol VL - 55 Suppl 1 N2 - At the present time, we have effective and potent antiparkinsonian drugs available which allow patients to have an acceptable functional capacity during the early years of Parkinson's disease. Yet, as time goes by, motor and functional deterioration develop, partly due to the presence of motor and non-motor complications. The conventional medication is unable to provide an adequate response if the motor fluctuations are beyond 3-4 hours of duration. At this point, it is reasonable to consider other therapies; among them subcutaneous apomorphine injection must be taken into account due to its simplicity and efficacy and later on, subcutaneous apomorphine infusion. Apomorphine is a very effective and clearly underused drug in the treatment of advanced Parkinson's disease. SN - 1576-6578 UR - https://www.unboundmedicine.com/medline/citation/23169231/[Limits_of_conventional_oral_and_transdermal_medication_in_Parkinson's_disease]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -